undamentalytics Newsletter
Sign in

Cerenome, Inc. income statement

In fiscal 2025, Cerenome, Inc. reported revenue of $5.2m, down 10.5% on the year before, operating income of −$15.3m (a -293.5% margin) and net income of −$22.4m, or −$0.29 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue68897555345654
Cost of revenue————————11————
Gross profit2445422203————
Research and development12101114171519161261011813
Selling and marketing711149963441————
General and administrative101315161616109869101218
Operating income−22−25−29−28−31−32−15−20−21−9−13−15−15−26
Interest expense12333433220010
Income before tax———————————−13−22—
Income tax——————0000000—
Net income−23−27−32−32−26−37−19−22−23−13−13−13−22−26
Diluted EPS−$7312.50−$6750.00−$0.06−$0.06−$0.04−$0.05−$0.21−$0.13−$617.25−$130.47−$0.42−$0.23−$0.29—
Diluted shares (average)—————————116m31m77m78m—
EBITDA−20−24−29−27−29−32−14−19−19−7−13−14−15−26

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CNSY vs INBSBMRA vs CNSYCNSY vs MCTACNSY vs ICCM

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Cerenome, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cerenome, Inc.